0399082 - ÚJF 2014 US eng A - Abstrakt
Lebeda, Ondřej - Ráliš, Jan - Hradilek, Pavel - Hanč, Petr - van Lier, E. J. - Zyuzin, A. - Moša, M.
Cyclotron produced Tc-99m: testing compatibility with established kits.
European Journal of Nuclear Medicine and Molecular Imaging. Springer. Roč. 40, 2 Supplement (2013), S424-S425. ISSN 1619-7070. E-ISSN 1619-7089.
[Annual Congress of the European Association of Nuclear Medicine (EANM). 19.10.2013-23.10.2013, Lyon]
Institucionální podpora: RVO:61389005
Klíčová slova: cyclotron U-120M * Tc-99m * 100Mo
Kód oboru RIV: BG - Jaderná, atomová a mol. fyzika, urychlovače

Aim Global shortage of 99Mo and anticipated shut-down of multiple aging reactors has triggered the development for alternative production routes of 99Mo and 99mTc. One of the most promising technologies is direct cyclotron production of 99mTc. It has already been proven that it is feasible to produce TBq amount of 99mTc by (p,2n) reaction on highly enriched 100Mo (24 MeV, 500 uA and 6h irradiation) while keeping levels of radionuclidic impurities sufficiently low for clinical applications. Significant progress was achieved also in R&D of separation process and recycling of the highly enriched targets. An outstanding challenge to be resolved is compatibility of commercially available kits for 99mTc radiopharmaceuticals with cyclotron-produced 99mTc. We have, therefore, tested several kits for routine production of widely used 99mTc radiopharmaceuticals with 99mTc produced on cyclotron U-120M at 24 MeV. Materials and Methods Thick targets from 99.03 % enriched 100Mo were irradiated on external 24MeV proton beam of the cyclotron U-120M at Nuclear Physics Institute, Rez. After the end of bombardment (EOB), the targets were processed on ACSI designed Cyclotec™ Tc-99m automated separation module. The final product in 0.9% NaCl was analyzed and combined with majority of kits for production of 99mTc radiopharmaceuticals. Each product was characterized by Methods recommended by the respective producer. Results and Conclusion In all the cases, prepared 99mTc radiopharmaceuticals complied with the tests for radiochemical purity as described by their respective producers. Moreover, in majority of cases, no radiochemical impurities were detected in the products at all, even if very low 99mTc concentrations were used for labellings (5 MBq/ml). From that point of view, we have not observed any difference between generator 99Mo/99mTc eluate and 99mTc solution prepared from proton-irradiated 100Mo targets on the Cyclotec™ Tc-99m automated separation module.
Trvalý link: http://hdl.handle.net/11104/0226460